PM
NAGE

Precept Management’s Niagen Bioscience NAGE Stock Holding History

Precept Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-200,000
Closed -$1.18M – 84
2017
Q4 		$1.18M Buy
+200,000
New +$1.08M 0.7% 37

Other funds holding NAGE

IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Precept Management's NAGE Position: Q1 2018 in Review

Precept Management sold out of Niagen Bioscience (NAGE) in Q1 2018, closing a stake of 200,000 shares — an estimated $1.18M sold.

Precept Management first reported a position in NAGE in Q4 2017 and held it in 1 quarter. The position peaked at $1.18M in Q4 2017. 58 funds tracked by Wall St. Rank hold NAGE as of Q1 2018.

  • Precept Management reported no remaining Niagen Bioscience position as of Q1 2018 after selling out during the quarter.
  • Precept Management sold 200,000 Niagen Bioscience shares in Q1 2018, an estimated $1.18M.
  • Precept Management first reported a position in Niagen Bioscience in Q4 2017 and held it in 1 quarter.
  • Precept Management's Niagen Bioscience position peaked at $1.18M in Q4 2017.
  • 58 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2018.

Based on Precept Management's 13F filing for Q1 2018, filed 15 May 2018.